...Following a run of partnerships with Asian companies, Numab has closed a series B round to...
...Numab since it closed a CHF7 million series A round in June 2015. Since then, Numab...
...particularly in Asia, where it now has six partnerships. While Numab CEO David Urech said Numab...

...in post-menopausal women at high risk of bone fracture. Numab, 3SBio partner for multispecific antibodies Numab...
...antibodies for cancer. Sunshine Guojian will develop and commercialize the compounds in Greater China, while Numab...
...in Numab’s series B financing. President of R&D and CSO of 3SBio Zhenping Zhu joined Numab’s...

...prophylactic under a deal with the Bill & Melinda Gates Foundation, and is collaborating with Numab...
...obesity, autoimmune and inflammatory diseases. In March, Intarcia exercised an option to obtain rights to Numab’s...

...in exchange for exclusive, Asian rights to develop and commercialize preclinical trispecific antibody ND021 from Numab...
...to the compound in China, including Hong Kong and Macau, Taiwan, South Korea and Singapore. Numab...
...retains rights elsewhere. The Phase Ib study will take place outside of China, according to Numab...

...NDA resubmission for its Type II diabetes therapy, Intarcia exercised an option to license from Numab...
...is a trispecific antibody fragment that blocks IL-17A and TNFα, and binds to serum albumin. Numab...
...CHF70 million ($69.9 million) and is eligible for up to double-digit tiered royalties. According to Numab's...

...for an undisclosed inflammatory indication using Numab’s discovery platform. Under the deal, Kaken will fund Numab’s...
...have an option to co-develop the candidate with Numab and obtain "certain" undisclosed commercial rights. Numab’s...
...scaffold’s kappa chain with a lambda cap sequence. The companies declined to disclose additional details. Numab...

...Numab’s discovery platform. Ono also received an option to acquire IP rights to the compound. Numab’s...
...Squibb Co. (NYSE:BMY, New York, N.Y.). Opdivo is a human IgG4 mAb against PD-1 . Numab...
...and milestones, plus tiered single- to double-digit royalties. The companies declined to provide further details. Numab...

...Numab’s discovery platform. Ono also received an option to acquire IP rights to the compound. Numab...
...The companies said the compound will “exploit one of Ono’s novel therapeutic approaches in immuno-oncology." Numab’s...
...to treat several cancers. Ono shares rights to Opdivo with Bristol-Myers Squibb Co. (NYSE:BMY). Jaime De Leon Numab AG Ono...

...to develop ITCA 650 combinations that include single chain antibody fragments under a deal with Numab AG...

...it said it would develop combinations with single chain antibody fragments via a collaboration with Numab AG...